Prochlorperazine-Induced Neuroleptic Malignant Syndrome: Case-Based Evidence and Translational Outlook

Study Background and Research Question

Neuroleptic malignant syndrome (NMS) is an infrequent yet life-threatening neurological emergency associated predominantly with antipsychotic therapy, but its presentation can be heterogeneous and easily misattributed to other acute disorders in complex patients. The recent case study by Zong-Jun Tee (American Journal of Emergency Medicine, 2024) addresses a rarely documented scenario: NMS induced by prochlorperazine—a dopamine antagonist more commonly prescribed as an antiemetic—at standard dosage in an elderly patient with multiple comorbidities. The report’s central aim is to illuminate the spectrum of clinical and laboratory findings in drug-induced NMS, refine differential diagnostic criteria, and inform optimal treatment strategies in such atypical contexts.

Key Innovation from the Reference Study

The reference case introduces several key advances in the clinical understanding of NMS. First, it systematically documents NMS triggered by prochlorperazine at commonly prescribed doses, challenging assumptions that only high-potency or prolonged antipsychotic exposure confers risk. Second, the report highlights the diagnostic dilemma posed by the absence of classic laboratory abnormalities (e.g., normal white blood cell count, electrolytes, and only modestly elevated creatine phosphokinase), reinforcing the primacy of clinical vigilance over reliance on routine biomarkers. Finally, the longitudinal tracking of therapeutic response provides practical guidance for managing NMS in patients with overlapping cardiovascular and metabolic comorbidities.

Methods and Experimental Design Insights

This single-patient case study employed a prospective observational design, with meticulous collection of temporal symptom progression, comprehensive neurological assessment, and serial laboratory and imaging evaluations. The patient, a 76-year-old male with longstanding hypertension, type 2 diabetes mellitus, and atrial fibrillation, presented with fever, altered consciousness, pronounced rigidity, and autonomic instability after two weeks of prochlorperazine (5 mg BID) for vertigo-induced nausea. Diagnostic work-up included:

• Serial neurological exams (including Glasgow Coma Scale scoring and deep tendon reflex assessment)
• Routine blood counts and biochemical panels
• Creatine phosphokinase (CPK) monitoring
• Brain imaging (non-contrast CT) to exclude acute intracranial events
• Cerebrospinal fluid (CSF) analysis to rule out infectious and inflammatory etiologies
• Continuous EEG monitoring for occult seizure activity

The diagnostic algorithm prioritized exclusion of serotonin syndrome, CNS infections, malignant hyperthermia, and catatonia, leveraging a combination of drug history, symptom chronology, and negative findings on imaging and CSF analysis. Treatment comprised intravenous lorazepam and oral amantadine, with careful hemodynamic monitoring and gradual medication tapering.

Core Findings and Why They Matter

The patient’s clinical evolution—marked by resolution of fever, rigidity, and altered mental status following targeted pharmacotherapy—supported the diagnosis of prochlorperazine-induced NMS. Importantly, the absence of significant leukocytosis, extreme CPK elevation, or metabolic derangement highlights the spectrum of NMS presentations and the limitations of laboratory confirmatory tests. As detailed in the reference study, full recovery was achieved with a regimen of IV lorazepam (1 mg q6h) and oral amantadine (100 mg q12h), with no sequelae upon follow-up. This case underscores the relevance of early recognition and immediate intervention—even at standard dosing levels—especially in geriatric patients susceptible to iatrogenic complications due to multimorbidity.

Comparison with Existing Internal Articles

While the primary case study focuses on acute neurological toxicity and pharmacovigilance, several internal articles provide complementary perspectives relevant to translational research and experimental modeling:

• Translating Mechanistic Insight into Next-Generation Neurotherapeutics discusses the utility of Morin (2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one) as a model compound for probing neuroprotective and mitochondrial pathways, which are also implicated in the pathophysiology of NMS and related syndromes.
• Morin in Translational Bioscience: Mechanistic Innovation explores how natural flavonoid antioxidants can modulate cellular stress responses, potentially informing future research into oxidative and metabolic contributors to drug-induced neurological emergencies.
• Morin: Natural Flavonoid Antioxidant for Advanced Research details workflow strategies for evaluating mitochondrial energy metabolism and neuroinflammation, approaches that could be adapted to experimental NMS models.

Although these resources do not directly address NMS, they provide foundational methodologies and mechanistic context for researchers seeking to develop in vitro or in vivo models of antipsychotic-induced neurotoxicity, including investigation of oxidative stress, inflammation, and mitochondrial dysfunction—processes relevant to the syndrome described in the reference case.

Limitations and Transferability

This report’s single-patient, observational framework limits the generalizability of its findings; larger cohort studies or mechanistic investigations are needed to further delineate risk factors and optimize therapeutic protocols for prochlorperazine-induced NMS. Additionally, the diagnostic reliance on clinical features in the absence of typical laboratory abnormalities underscores the risk of underdiagnosis in broader populations. While the case provides a pragmatic template for acute management, its applicability to patients with more severe biochemical derangement or atypical symptom profiles warrants further validation.

Protocol Parameters

• Prochlorperazine exposure: 5 mg/tablet twice daily for 14 days preceding NMS onset; monitor closely in geriatric and comorbid patients.
• NMS symptom assessment: Prioritize fever, rigidity, altered mental status, and autonomic instability over laboratory markers.
• Treatment protocol: Initiate IV lorazepam (1 mg every 6 hours) and oral amantadine (100 mg every 12 hours); titrate and taper based on clinical improvement.
• Diagnostic work-up: Exclude alternative etiologies (e.g., serotonin syndrome, CNS infection) with targeted imaging, CSF analysis, and medication review.
• Follow-up: Continue amantadine on discharge until sustained symptom resolution is confirmed.

Research Support Resources

Researchers modeling neuroleptic malignant syndrome or investigating mitochondrial and neuroprotective pathways may benefit from integrating natural flavonoids such as Morin (SKU C5297; 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one), which demonstrates robust antioxidant, anti-inflammatory, and fluorescent chelating properties. According to the internal bioanalytical profile, Morin’s dual functionality as both a mitochondrial modulator and a fluorescent aluminum ion probe supports advanced mechanistic and diagnostic workflows. APExBIO provides high-purity Morin suitable for both cellular and biochemical assays, facilitating translational research at the neuroimmune and metabolic interface.